Check Medinfo

Information for patients and healthcare professionals.

DE FR IT

Product

Product hero

We are proud to develop, produce, license and commercialise a biosimilar that meets the highest medical standards: Ranibizumab, biosimilar to Lucentis, for the treatment of e.g. age related macular degeneration AMD.

Ranibizumab, our product, is a biosimilar to Lucentis®
Different brands, one and the same product.
VL UNT BIOEQ 652982 lowres

Ranibizumab is approved by the US Food and Drug Administration FDA, branded as Cimerli, the UK Medicines and Healthcare Regulatory Agency, branded as Ongavia, by the European Commission and Swissmedic, branded as Ranivisio, and by various other competent authorities worldwide.

Press releases

EC Approval FYB/Ranivisio

Aug 29, 2022

PDF

FDA approves CIMERLI, the first biosimilar interchangeable with Lucentis

Aug 03, 2022

PDF

Grant of marketing authorisation in UK

May 17, 2022

PDF

Bioeq AG and MS Pharma

Dec 14, 2021

PDF

Bioeq AG and Teva

Jun 28, 2021

PDF

Bioeq AG and Coherus

Nov 06, 2019

PDF
VL UNT BIOEQ 652758 lowrest

Now: What could your career be, our jobs, who we are, and what our product is, — thank you for being interested in Bioeq and our fantastic team.

VL UNT BIOEQ 710098 lowres